ESTRO 2023 - Abstract Book

S1165

Digital Posters

ESTRO 2023

Materials and Methods Multicentre study with prospective data collection, where DNA samples were collected from 264 pts with primary LC from February/2013-December/2020 to perform genotyping analysis looking for associations between hematological toxicity and SNPs of HSPB1 gen. Genotyping analysis was performed on DNA isolated from blood samples by polymerase chain reaction (PCR). The acute HT of the analysis were assessed using the CTCAEv.5 scale. Cox proportional hazards analysis was performed to assess the effect of different genotypes. Results Median follow-up of 21 months (6-76m), median age was 63 years (33-83). 85,6% were male and 14,4% female. 87,8% received QT treatment (platinum schedules). According to clinical stage, 9,4% (25) had stage I-II, 38,6%(102) IIIA, 46,2% (122) IIIB and 5,7%(15) IV. The most frequent histologies were 41% (110) squamous cell carcinoma, 25% (67) adenocarcinoma and 27,6% (73) small cell. Multivariate analysis showed that the HSPB1 rs7459185 GG genotype (vs GC /CC) was associated with HT grade 2 with a HR of 1.462 (95%CI 1.054-2.029, p= 0.023). Similarly, those patients with the GG genotype had an increased risk of overall HT > grade 3 with a HR of 1.531 (95%CI 1.016-2.30, p= 0.042) compared to GC/CC. Conclusion Our findings show a relationship between SNPs rs7459185 of the HSPB1 gene in the development of HT in patients with PC. These response markers could be used as biomarkers for future individual therapeutic schemes. 1 CNAO National Center for Oncological Hadrontherapy, Radiation Oncology Unit, Clinical Department, Pavia, Italy; 2 CNAO National Center for Oncological Hadrontherapy , Clinical Bioengineering Unit, Clinical Department, Pavia, Italy; 3 AOU Città Della Salute e Della Scienza, University of Turin, Division of Cardiology, Department of Medical Sciences, Torino, Italy; 4 Fondazione IRCCS Policlinico San Matteo, Department of Cardiology , Pavia, Italy; 5 CNAO National Center for Oncological Hadrontherapy, Medical Physics Unit, Clinical Department, Pavia, Italy; 6 Fondazione IRCCS Istituto Nazionale dei Tumori, Unit of Radiation Oncology 1, Milan, Italy; 7 Politecnico di Milano Department of Electronics, Information and Bioengineering, and CNAO National Center for Oncological Hadrontherapy, Clinical Bioengineering Unit, Clinical Department, Milan, Pavia, Italy; 8 Fondazione IRCCS Policlinico San Matteo, Coronary Care Unit and Laboratory of Clinical and Experimental Cardiology , Pavia, Italy Purpose or Objective Finding early predictors of late cardiotoxicity after a thoracic RT, which represents a significant risk factor for premature death, is warranted. This study aims to assess the effect of thoracic carbon ion radiotherapy (CIRT) on serum levels of C reactive protein (CRP), troponin-I (TnI) and NT-ProBNP. Materials and Methods Clinical, laboratoristic and dosimetric data from 15 consecutive pts (median age: 67 years, range: 38-79, 53% female) treated with pencil beam CIRT (median total dose 56 Gy [RBE], range: 40-70 Gy [RBE]) for a para/intra-cardiac tumour at a single center were retrospectively reviewed. Most patients (10, 67%) were treated for thoracic localization of sarcomas (leiomyosarcomas N=3, chondrosarcomas N=2, liposarcomas N=2, hemangioendothelioma N=1, fibromyxoid sarcoma N=1, pleomorphic sarcoma N=1), 2 for adenoid cystic carcinomas, the rest for thyroid carcinoma (N=1), renal clear cell carcinomas (N=1) and colon adenocarcinoma (N=1). Laboratoristic parameters were collected before, during, at the end of CIRT and at 3, 6 and 12 months of follow-up (m-FU). Wilcoxon signed-rank test was applied to evaluate changes during treatment (baseline to CIRT-end) and after treatment (CIRT-end to 6m-FU). Any relationship between dosimetric/clinical data and laboratoristic changes over time was explored using Spearman correlation test and point biserial correlation index when appropriate. The significance level was set to 0.05. Results Median FU was 6 months (range: 0 to 12 months). At baseline, diabetes (p= 0,035) and hypercholesterolemia (p=0,023) were associated with higher CRP value; hypercholesterolemia (p=0,045) with higher TnI values; tyroid disease (p<0.001) with higher NT-ProBNP values. Cardiovascular comorbidities, disease history, age and gender did not influence laboratoristic changes during and after CIRT. TnI and CRP values, both within the normal range, were unchanged, while NT-ProBNP values reported a significant increase during CIRT (from 56.3 to 100 pg/mL, p=0.045) and a trend towards decrease after (from 100 to 64 pg/mL, p=0.064). NT-ProBNP reduction related with the minimum dose (Dmin) to Left atrium (p=0.013, r=0.69), the maximum dose (Dmax) to left main coronary artery (p=0.012, r=0.7) and the Dmax to circumflex artery (p=0.01, r=0.71). There were no strong nor moderate significant correlations between NT-ProBNP variations and other dosimetric parameters on different cardiac structures. PO-1439 CIRT-induced cardiac biomarkers changes in patients with para/intra-cardiac tumours A. Barcellini 1 , G. Fontana 2 , V. Dusi 3 , A. Greco 4 , A. Vai 5 , S. Molinelli 5 , A. Mirandola 5 , A. Ghirelli 1 , D. Zambrino 1 , C. Sangalli 6 , G. Baroni 7 , R. Rordorf 8 , V. Vitolo 1 , E. Orlandi 1